Pfizer ROA 1986-2025 | PFE

Current and historical return on assets (ROA) values for Pfizer (PFE) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Pfizer ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2025-06-30 $10.75B $206.10B 5.08%
2025-03-31 $7.88B $208.03B 3.68%
2024-12-31 $8.03B $213.40B 3.69%
2024-09-30 $4.25B $219.48B 1.93%
2024-06-30 $-2.60B $216.19B -1.18%
2024-03-31 $-0.31B $221.10B -0.14%
2023-12-31 $2.12B $226.50B 0.99%
2023-09-30 $10.48B $215.02B 5.06%
2023-06-30 $21.47B $220.17B 10.63%
2023-03-31 $29.05B $195.62B 14.83%
2022-12-31 $31.37B $197.21B 16.26%
2022-09-30 $29.77B $195.35B 15.75%
2022-06-30 $29.31B $195.29B 15.85%
2022-03-31 $24.97B $183.84B 13.98%
2021-12-31 $21.98B $181.48B 12.75%
2021-09-30 $19.43B $179.19B 11.74%
2021-06-30 $12.76B $169.92B 7.71%
2021-03-31 $10.68B $158.82B 6.38%
2020-12-31 $9.16B $154.23B 5.41%
2020-09-30 $7.73B $178.98B 4.48%
2020-06-30 $13.94B $177.93B 8.17%
2020-03-31 $15.50B $166.34B 9.38%
2019-12-31 $16.03B $167.59B 9.87%
2019-09-30 $16.22B $170.45B 10.11%
2019-06-30 $12.65B $156.20B 7.92%
2019-03-31 $11.48B $155.42B 7.09%
2018-12-31 $11.15B $159.42B 6.79%
2018-09-30 $23.82B $167.84B 14.24%
2018-06-30 $22.55B $164.98B 13.39%
2018-03-31 $21.75B $164.61B 12.85%
2017-12-31 $21.31B $171.80B 12.51%
2017-09-30 $9.81B $172.15B 5.76%
2017-06-30 $8.32B $168.56B 4.84%
2017-03-31 $7.30B $168.78B 4.23%
2016-12-31 $7.22B $171.62B 4.22%
2016-09-30 $6.27B $178.43B 3.69%
2016-06-30 $7.04B $170.66B 4.19%
2016-03-31 $7.62B $162.93B 4.61%
2015-12-31 $6.96B $167.38B 4.22%
2015-09-30 $8.36B $170.87B 5.07%
2015-06-30 $8.90B $160.88B 5.39%
2015-03-31 $9.18B $160.64B 5.46%
2014-12-31 $9.14B $167.57B 5.35%
2014-09-30 $10.48B $171.36B 6.09%
2014-06-30 $10.40B $172.61B 6.01%
2014-03-31 $21.58B $171.81B 12.35%
2013-12-31 $22.00B $172.10B 12.32%
2013-09-30 $25.75B $175.52B 14.15%
2013-06-30 $26.37B $179.34B 14.35%
2013-03-31 $15.53B $187.40B 8.41%
2012-12-31 $14.57B $185.80B 7.91%
2012-09-30 $9.69B $182.60B 5.25%
2012-06-30 $10.22B $182.84B 5.43%
2012-03-31 $9.58B $185.68B 5.00%
2011-12-31 $10.01B $188.00B 5.17%
2011-09-30 $11.46B $196.13B 5.86%
2011-06-30 $8.59B $195.90B 4.42%
2011-03-31 $8.45B $194.96B 4.38%
2010-12-31 $8.26B $195.01B 4.27%
2010-09-30 $6.13B $191.42B 3.10%
2010-06-30 $8.15B $191.07B 4.40%
2010-03-31 $7.93B $195.11B 4.61%
2009-12-31 $8.64B $212.95B 5.60%
2009-09-30 $8.13B $141.29B 6.32%
2009-06-30 $7.53B $139.34B 6.17%
2009-03-31 $8.05B $122.93B 6.91%
2008-12-31 $8.10B $111.15B 7.02%
2008-09-30 $10.56B $115.25B 9.07%
2008-06-30 $9.05B $116.52B 7.88%
2008-03-31 $7.54B $118.55B 6.65%
2007-12-31 $8.14B $115.27B 7.32%
2007-09-30 $14.87B $109.03B 13.35%
2007-06-30 $17.47B $110.40B 15.70%
2007-03-31 $18.62B $110.48B 16.69%
2006-12-31 $19.34B $115.55B 17.24%
2006-09-30 $12.62B $108.59B 11.22%
2006-06-30 $10.85B $111.55B 9.60%
2006-03-31 $11.90B $112.96B 10.51%
2005-12-31 $8.09B $116.97B 6.99%
2005-09-30 $8.18B $110.34B 6.98%
2005-06-30 $9.93B $112.33B 8.27%
2005-03-31 $9.33B $122.94B 7.65%
2004-12-31 $11.36B $123.08B 9.32%
2004-09-30 $9.14B $122.23B 7.59%
2004-06-30 $8.03B $119.96B 6.70%
2004-03-31 $1.58B $122.29B 1.30%
2003-12-31 $3.91B $116.78B 3.78%
2003-09-30 $6.17B $120.06B 7.18%
2003-06-30 $6.28B $124.26B 9.36%
2003-03-31 $11.83B $52.93B 25.34%
2002-12-31 $9.13B $46.36B 20.85%
2002-09-30 $8.23B $44.88B 19.60%
2002-06-30 $7.95B $42.57B 19.65%
2002-03-31 $7.82B $41.32B 20.03%
2001-12-31 $7.79B $39.15B 20.76%
2001-09-30 $7.25B $38.81B 20.09%
2001-06-30 $6.54B $36.94B 18.81%
2001-03-31 $5.86B $35.15B 17.47%
2000-12-31 $3.73B $33.51B 12.50%
2000-09-30 $3.26B $33.49B 12.27%
2000-06-30 $3.30B $32.04B 14.17%
2000-03-31 $2.86B $20.23B 14.16%
1999-12-31 $3.88B $20.57B 19.50%
1999-09-30 $3.63B $20.24B 18.82%
1999-06-30 $3.63B $19.64B 19.33%
1999-03-31 $3.55B $19.03B 19.72%
1998-12-31 $3.43B $18.30B 19.89%
1998-09-30 $3.28B $18.18B 19.86%
1998-06-30 $2.47B $16.51B 15.67%
1998-03-31 $2.30B $15.96B 14.77%
1997-12-31 $2.21B $15.34B 14.40%
1997-09-30 $2.16B $15.35B 14.20%
1997-06-30 $2.08B $15.73B 13.83%
1997-03-31 $2.01B $15.05B 13.90%
1996-12-31 $1.93B $14.67B 13.76%
1996-09-30 $1.84B $14.62B 13.57%
1996-06-30 $1.75B $13.62B 13.35%
1996-03-31 $1.67B $13.17B 12.92%
1995-12-31 $1.57B $12.73B 12.33%
1995-09-30 $1.50B $12.82B 12.11%
1995-06-30 $1.41B $12.95B 11.98%
1995-03-31 $1.35B $12.52B 12.22%
1994-12-31 $1.30B $11.10B 12.60%
1994-09-30 $1.25B $10.40B 12.71%
1994-06-30 $0.70B $10.10B 7.22%
1994-03-31 $0.70B $9.64B 7.20%
1993-12-31 $0.66B $9.33B 6.76%
1993-09-30 $0.65B $9.88B 6.61%
1993-06-30 $1.16B $10.02B 11.76%
1993-03-31 $1.13B $9.72B 11.55%
1992-12-31 $1.08B $9.59B 11.11%
1992-09-30 $0.80B $10.13B 8.23%
1992-06-30 $0.78B $9.56B 8.23%
1992-03-31 $0.73B $9.47B 7.95%
1991-12-31 $0.72B $9.64B 7.96%
1991-09-30 $0.88B $9.01B 9.82%
1991-06-30 $0.84B $8.83B 9.58%
1991-03-31 $0.82B $8.81B 9.46%
1990-12-31 $0.80B $9.05B 9.53%
1990-09-30 $0.73B $8.53B 8.91%
1990-06-30 $0.71B $8.10B 8.82%
1990-03-31 $0.69B $7.96B 8.76%
1989-12-31 $0.68B $8.33B 8.71%
1989-09-30 $0.74B $7.73B 9.63%
1989-06-30 $0.74B $7.65B 9.75%
1989-03-31 $0.81B $7.60B 10.94%
1988-12-31 $0.79B $7.64B 10.89%
1988-09-30 $0.79B $7.30B 11.09%
1988-06-30 $0.76B $7.20B 11.23%
1988-03-31 $0.72B $6.96B 11.31%
1987-12-31 $0.69B $6.92B 11.59%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $201.199B $100.330B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12